CION Ameerpet
If your ovarian cancer has come back, the honest position is this: a relapse is usually treatable, often for years, even when it can no longer be called curable. What changes is the question being asked. First-line treatment aimed at clearing the disease. From here, the aim is control — holding the cancer back, keeping symptoms quiet, and protecting the life you are living while you do it.
A relapse is not a sign that your first treatment failed, and it is not something you missed. Most high-grade ovarian cancers respond well to first-line chemotherapy — and in advanced disease, the majority come back at some point anyway. Microscopic cells survive treatment, sit quietly in the abdomen, and eventually grow again. That is the biology of this disease, not a verdict on your care or your choices.
Recurrent ovarian cancer treatment starts from a different question than first-line treatment did. The first plan asked how to clear the disease completely. The second asks how to control it for as long as possible, with the fewest side effects, while you carry on with your life. That shift changes what counts as a good result: months of stability on a manageable regimen can be a better outcome than a harder treatment that shrinks a scan and flattens you for a year.
The other thing that changes is pace. First-line treatment often begins within days of diagnosis. A relapse, unless the bowel is threatened or you are unwell, almost never needs to be treated the same week. There is usually time to gather the reports, retest the tumour biology, take a second opinion and choose deliberately — and using that time well tends to produce a better plan than rushing does.
Recurrence is the usual course of advanced ovarian cancer, which is why a good first-line plan is built with a second and third line already in mind.
It is more honest to say this plainly. Relapsed disease can often be controlled for years across several lines of treatment, but a second complete cure is uncommon in advanced cases.
A rising marker or a small spot on a scan is information, not an emergency. Read how a recurrence is classified before agreeing to anything.
A rising CA-125 does not, by itself, mean treatment must start now. In the MRC OV05/EORTC 55955 trial, women in remission after first-line treatment had regular CA-125 tests; half began chemotherapy as soon as the marker rose, half waited until symptoms or scan changes appeared. Early treatment started chemotherapy roughly five months sooner — and made no difference to how long women lived, while quality of life declined earlier in the early-treatment group. This is why a specialist reads the whole picture — symptoms, scan, the interval since platinum, your own priorities — instead of reacting to one number. Source: Rustin GJS et al., The Lancet (2010); NCCN Ovarian Cancer guidelines.
The interval between your last platinum-based chemotherapy and the disease returning predicts, better than anything else available, whether platinum will work again. It is the first thing a specialist calculates, and it sets the shape of everything that follows.
| Interval since the last platinum chemotherapy | What it usually indicates | Where treatment usually starts |
|---|---|---|
| Progression during platinum treatment (refractory) | The disease grew while on platinum. Re-treating with platinum is very unlikely to help. | A non-platinum single agent, a clinical trial, or symptom-directed care alone if you are unwell. |
| Under 6 months (platinum-resistant) | Platinum is unlikely to control the disease a second time, though the six-month line is a convention rather than a switch. | Non-platinum single-agent chemotherapy, often weekly and gentler; anti-angiogenic therapy added in selected women; trials. |
| 6 to 12 months (partially platinum-sensitive) | Platinum may still work, but less reliably. Biology, symptoms and how you tolerated the last course all weigh in here. | A platinum combination is often still reasonable; a non-platinum route is a legitimate alternative. A genuine discussion, not a formula. |
| More than 12 months (platinum-sensitive) | Platinum is likely to work again, sometimes very well. | Platinum-based combination chemotherapy, followed by maintenance if there is a response; surgery considered in carefully selected women. |
| Low-grade or indolent relapse, any interval | Slow-growing disease that often responds poorly to chemotherapy but well to hormonal treatment. | Hormonal treatment, or close monitoring where the disease is small and causing nothing. |
*The six-month cut-off comes from older trial design, not from biology, and specialists increasingly treat it as a spectrum. The fuller explanation sits on platinum-sensitive versus platinum-resistant recurrence, and the options after a short interval are set out under platinum-resistant ovarian cancer.
Almost every plan is built from these components, alone or in combination. Which ones are open to you depends on the interval, the tumour biology, how much disease there is, and what your body has already been through.
For disease that returned well after the last platinum course, going back to platinum with a partner drug is the standard backbone. Response is meaningfully more likely the longer the interval, and many women get a second remission that lasts a useful length of time. Cycles usually run every three weeks, with a mid-course scan to confirm it is working before completing the course.
The practical questions are tolerance and allergy. Cumulative nerve damage from earlier treatment, hearing changes and kidney function all influence the choice of partner drug and the schedule, and a weekly schedule is often gentler. Platinum allergy becomes commoner with repeated exposure, which is why your team asks about itching, flushing or breathlessness during previous infusions.
If chemotherapy achieves a response, maintenance treatment aims to hold that response for longer rather than to shrink anything further. PARP-inhibitor-class tablets are the main option, and the benefit is greatest where the tumour carries a BRCA variant or shows homologous recombination deficiency. That is why testing matters even at relapse, and why we retest when it was never done at diagnosis.
Maintenance is a daily tablet taken at home, with blood counts monitored regularly, continued while it is working and tolerated. Whether it fits depends partly on what you have already had: if PARP-inhibitor-class treatment followed your first-line chemotherapy, using the same class again after a later platinum response is a more nuanced decision and belongs on a tumour-board agenda.
Treatments in the anti-angiogenic class work by cutting off the tumour's blood supply rather than by killing dividing cells. Added to chemotherapy at relapse, this class improves the chance and the duration of response for many women, including some with platinum-resistant disease and troublesome ascites.
It does not suit everyone. Uncontrolled blood pressure, significant protein in the urine, recent major surgery, bleeding, or bowel involvement that raises the risk of a perforation all count against it. These are real risks with real warning signs, which is why blood pressure and urine are checked before every cycle rather than occasionally.
Where platinum is unlikely to work — a short interval, or progression during platinum — treatment moves to a single non-platinum drug, frequently given weekly. Weekly dosing usually means fewer severe dips in blood counts, less hair loss with some agents, and a rhythm that fits around normal life better than a three-weekly cycle does.
Expectations should be set honestly here. Response rates for single agents in platinum-resistant disease are modest, and the realistic aim is disease control and symptom relief rather than dramatic shrinkage. If two successive lines produce no benefit, cycling through further chemotherapy rarely helps, and a trial or symptom-focused care is often the better path. See options in platinum-resistant disease.
Some recurrent tumours carry a target that a specific class of treatment can act on — antibody-drug-conjugate-class treatment where the tumour tests positive for the relevant receptor, or immunotherapy where mismatch-repair deficiency is found. These options exist only where a test supports them, which is why re-testing archived tissue, or biopsying an accessible deposit, can genuinely change what is available to you.
Be wary of any plan that promises a targeted treatment without the test that justifies it. Testing first is not a delaying tactic. It is the only way to know whether a targeted route is real in your case or a false hope that costs you months.
A second operation helps a narrow, well-defined group: women whose disease returned well after platinum, who had all visible disease removed at the first operation, who are in good general health, and who have no ascites. In that group, removing every visible deposit has been shown in randomised trials to improve outcomes. Where complete removal is not achievable, the same trials show no benefit and real harm from the surgery itself — and the trials have not all agreed, which is exactly why selection is argued case by case rather than assumed.
At CION, ovarian cancer surgery — secondary cytoreduction included — is coordinated with specialist gynaecologic-oncology surgeons at partner centres, and may be billed there. We say that upfront rather than letting you discover it at admission. Our part is the assessment, the tumour-board judgement on whether an operation is genuinely appropriate, and every piece of your systemic treatment before and after it.
Heated intraperitoneal chemotherapy (HIPEC) and intraperitoneal chemotherapy deliver drug directly into the abdominal cavity at the time of surgery. The strongest evidence sits at interval debulking during first-line treatment, not at relapse, where the role remains unsettled. Both are coordinated at specialist partner centres, and neither should be offered to you as a routine answer for recurrent disease.
A clinical trial is often the most valuable option at relapse, particularly once platinum stops working, because it is the only route to treatments not yet in standard use. Ask early rather than after several lines, since eligibility usually depends on how much treatment you have already had. Read more about clinical trials in ovarian cancer.
Relapsed disease is managed alongside its complications, and several of these are far easier to treat early than late. None of them means your treatment has stopped working — they mean your team needs to know today.
The pattern of a bowel obstruction, the commonest serious complication of recurrent ovarian cancer. Handled far better early. Do not wait it out at home.
Ascites that returns and tightens over days causes breathlessness and poor eating. Drainage plus a change of systemic plan usually settles it.
Fluid around the lung, a clot, or anaemia — all common in relapse, all treatable, none of them safe to watch from home.
Clots are markedly more common in ovarian cancer. One swollen calf, or sudden chest pain with breathlessness, needs assessment the same day.
Treat this as an emergency at any point in the cycle. Go to the nearest emergency department and say that you are on chemotherapy.
Escalating pain needs a review, not endurance. Uncontrolled pain also makes every other decision on this page far harder to think through.
Between appointments, call the number on your treatment card. If you cannot reach anyone and any of the above applies, attend an emergency department and take your treatment summary with you.
Bring your scans, your first-line records and your CA-125 results. In 45 minutes a specialist can tell you what the interval and the biology actually allow, whether surgery or a trial belongs in the conversation, and what each route would cost.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring the reports you have — we will tell you plainly what the options are, including the ones we would coordinate elsewhere.
A good plan is assembled in a sequence. Skipping steps — especially the testing ones — is how women end up on a treatment that was never likely to help them.
A CA-125 that rises on a single reading is not a relapse. Two consistent rises, symptoms, or a scan change together make the diagnosis. A CT of the chest, abdomen and pelvis maps what has come back and where. Occasionally a biopsy is worthwhile, either because the picture is atypical or because fresh tissue allows better testing.
How long since the last platinum, how many sites, how fast it has moved, whether there is ascites, and whether the bowel is at risk. A single deposit two years on is a different problem from widespread disease four months on, even though both are called recurrence.
BRCA and HRD testing, where it was never done, changes what maintenance is available and can matter for your family too. Genetic counselling and testing are delivered in-house at CION, and results usually arrive in time to inform the plan rather than too late to use.
This is a selection question, not a preference. Complete removal at the first operation, good general health, no ascites and a long interval point towards benefit; anything less usually does not. Where it is appropriate, we coordinate the operation with specialist gynaecologic-oncology surgeons at partner centres.
A platinum combination or a non-platinum single agent, with or without anti-angiogenic therapy, and what maintenance follows a response. Residual neuropathy, kidney function, blood counts and past allergic reactions narrow the list before preference comes into it. Every case is discussed at a tumour board rather than settled by one doctor.
Set the scan interval, the marker checks and the point at which you would stop or switch before the first cycle, rather than during a bad week. Ask about trials at this stage too, while eligibility is still wide. Written down, the next decision becomes far less frightening.
Bring these to a second opinion: the first-line chemotherapy record with dates, the operation note, the histopathology report, any BRCA or HRD result, and the last two scans on disc rather than as printed reports. A full picture of ovarian cancer treatment in Hyderabad is set out separately.
A recurrence consultation is not a five-minute appointment. It means going through the first-line record, the operation note, the pathology and the scans, working out the real interval, checking what testing exists and what is missing, then explaining the options in an order that makes sense. Your first consultation at CION is free and runs to about 45 minutes, and every case is discussed at a tumour board rather than decided by one doctor alone.
What we deliver ourselves, we say so. Chemotherapy, maintenance therapy, genetic counselling, BRCA and HRD testing, nutrition support and follow-up are in-house at CION, across more than 35 centres in Telangana and Andhra Pradesh, so cycles and blood tests can happen near where you live instead of requiring a trip into the city each time. What we coordinate, we also say plainly: all ovarian cancer surgery including secondary cytoreduction, along with HIPEC, intraperitoneal chemotherapy and PET-CT, is arranged with specialist partner centres and may be billed there.
Second opinions at relapse are worth having, including on plans made elsewhere. There is no pressure to move your care — a fair number of women take a written opinion back to their existing oncologist, which is a perfectly reasonable outcome. If you want the options costed before deciding, ask for a cost estimation at the consultation, including what Aarogyasri or your insurance is likely to cover.
Free, unhurried, and long enough to read the whole first-line record properly rather than only the most recent scan report.
Medical oncology, imaging and pathology review relapse plans together — particularly where surgery or a trial is being considered.
Genetic counselling with BRCA and HRD testing at CION, so maintenance decisions rest on your biology rather than on an assumption.
Surgery, HIPEC, intraperitoneal chemotherapy and PET-CT are delivered at specialist partner centres and may be billed there. You hear that from us upfront.
Search for survival after an ovarian cancer recurrence and you will find numbers that look precise and feel devastating. Most of them deserve caution. They are historical, drawn from women treated before maintenance therapy and BRCA-guided decisions existed. They average across platinum-sensitive and platinum-resistant disease, across high-grade and low-grade tumours, and across women who had complete surgery and women who did not. Those groups run very different courses, and an average across them describes none of them.
What can be said honestly is that the range is wide. Some women live for many years through several lines of treatment with long gaps in between; for others the disease moves quickly. The interval, the biology, how much disease there is and how you respond to the next line tell your oncologist far more than any published median. If you want a figure to plan around, ask your own team what they consider realistic in your situation — and ask them what would change it.
CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. That is one-year survival across the whole treated population — not a cure rate, and not a prediction for any individual.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
Published recurrence survival data is historical and averaged across sensitive and resistant disease, different subtypes and different surgical results. It describes groups, never you.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own outlook with your treating oncologist.
In most cases of advanced disease, no — and it is more useful to be told that plainly than to be left guessing. What recurrent ovarian cancer usually can be is controlled, sometimes for years, across several lines of treatment with good stretches in between. A small number of women with a single site of relapse, a long interval since platinum chemotherapy and complete surgical removal do achieve very long remissions. For everyone else the realistic aim is holding the disease back while protecting quality of life. That is not a lesser goal. Many women live well for a long time on that footing, and the treatments supporting it have improved considerably over the last decade.
Ovarian cancer recurrence treatment is chosen mainly on the time since your last platinum-based chemotherapy. If the interval was long, a platinum combination is usually offered again, often followed by maintenance treatment if it works. If the disease returned quickly, a non-platinum single agent, usually weekly, is the more sensible starting point, sometimes with anti-angiogenic therapy added. Where the tumour carries a BRCA variant or shows homologous recombination deficiency, PARP-inhibitor-class maintenance becomes important after a response. Surgery is considered only in a carefully selected group and is coordinated with partner centres. Hormonal treatment suits slow-growing low-grade disease, and clinical trials are worth asking about early rather than late.
Usually not immediately, and this is one of the most important things to understand about recurrence. A randomised trial compared starting chemotherapy as soon as the marker rose against waiting for symptoms or scan changes. Early treatment brought chemotherapy forward by roughly five months and did not help women live longer, while quality of life fell sooner in the early group. A rising CA-125 does justify a scan and a proper discussion, and if the disease is threatening the bowel or causing symptoms, treatment starts. But a rising number in a woman who feels well is a reason to plan carefully, not to begin chemotherapy that week.
Often yes, if enough time has passed. The longer the gap since your last platinum-based chemotherapy, the more likely platinum is to work again, which is why the interval is calculated before anything else is decided. Two things can change that plan. First, side effects that never fully resolved — particularly numbness or tingling in the hands and feet — may push your team towards a different partner drug or a gentler weekly schedule. Second, allergic reactions to platinum become commoner with repeated exposure, so any itching, flushing or breathlessness during earlier infusions must be mentioned. Where platinum is genuinely off the table, a non-platinum single agent takes its place.
For a minority of women, yes, and for them it can be worthwhile. The evidence points in one direction: a second operation helps when every visible deposit can be removed, and does not help — while carrying real risk — when it cannot. The women most likely to benefit had all visible disease removed at the first operation, are in good general health, have no ascites, and relapsed well after finishing platinum chemotherapy. Randomised trials have not all agreed, so this is argued case by case at a tumour board rather than assumed. At CION any such surgery is coordinated with specialist gynaecologic-oncology surgeons at partner centres, and may be billed there.
That is described as platinum-resistant disease, and while it narrows the options it does not close them. Platinum is unlikely to control the disease a second time, so treatment usually moves to a non-platinum single agent, often given weekly, which many women tolerate better than three-weekly cycles. Anti-angiogenic therapy added to that chemotherapy helps some women, particularly where ascites is a problem. Biomarker-guided treatment may be available where testing supports it, and this is the point at which a clinical trial is most worth asking about. Set expectations honestly with your oncologist: here the aim is disease control and symptom relief rather than dramatic shrinkage.
The first consultation is free and runs to about 45 minutes, and second opinions on plans made elsewhere are welcome. CION delivers medical oncology in-house: chemotherapy, maintenance therapy, genetic counselling with BRCA and HRD testing, nutrition support and follow-up, across more than 35 centres in Telangana and Andhra Pradesh, so most of your treatment can happen near where you live. Ovarian cancer surgery including secondary cytoreduction, along with HIPEC, intraperitoneal chemotherapy and PET-CT, is coordinated with specialist partner centres and may be billed there — we tell you that upfront. Every relapse plan is discussed at a tumour board, and you can ask for a written cost estimate at the consultation.